Isoprinosine, pills 500mg 20pcs

Composition

of 1 tab.

inosine pranobex 500 mg.

Auxiliary substances:  

mannitol,

wheat starch,

povidone,

magnesium stearate.

Pharmacological action

Isoprinosinee is a synthetic complex purine derivative with immunostimulating activity and non-specific antiviral effect.

Restores the functions of lymphocytes under conditions of immunosuppression, increases blastogenesis in the population of monocytic cells, stimulates the expression of membrane receptors on the surface of T-helper cells, prevents a decrease in the activity of lymphocytic cells under the influence of glucocorticosteroids, normalizes the inclusion of thymidine in them.

Isoprinosinee has a stimulating effect on the activity of cytotoxic T-lymphocytes and natural killers, the functions of T-suppressors and T-helpers, increases the production of immunoglobulin (lg) G, interferon-gamma, interleukins (IL)-1 and IL-2, reduces the formation of pro-inflammatory cytokines-IL-4 and IL-10, potentiates the chemotaxis of neutrophils, monocytes and macrophages.

The drug exhibits antiviral activity in vivo against viruses:

• Herpes simplex.
• Cytomegalovirus.
• The measles virus.
• Human T-cell lymphoma virus type III.
• Polioviruses.
• Influenza A and B.
• ESNO virus (enterocytopathogenic human virus).
• Encephalomyocarditis.
• Equine encephalitis.

The mechanism of antiviral action of Isoprinosinee is associated with inhibition of viral RNA and the enzyme dihydropteroate synthetase, which is involved in the replication of some viruses, enhances the synthesis of lymphocyte mRNA suppressed by viruses, which is accompanied by suppression of viral RNA biosynthesis and translation of viral proteins, and increases the production of interferons with antiviral properties by lymphocytes-alpha and gamma.

When combined, it enhances the effect of interferon-alpha, antiviral agents acyclovir and zidovudine.

Pharmacokinetics

After oral use, the drug is well absorbed from the gastrointestinal tract. The maximum concentration of ingredients in the blood plasma is determined after 1-2 hours.

It is rapidly metabolized and excreted through the kidneys. It is metabolized similarly to endogenous purine nucleotides to form uric acid. 1 M-M-dimethylamino-2-propranolone is metabolized to N-oxide, and para-acetamidobenzoate is metabolized to o-acylglucuronide.

No accumulation of the drug in the body was detected.

The elimination half-life is 3.5 hours for N-N-dimethylamino-2-propranolone and 50 minutes for para-acetamidobenzoate. Elimination of the drug and its metabolites from the body occurs within 24-48 hours.

Indications

• Flu.
• Acute respiratory viral infections.
• Infections caused by Herpes simplex virus types 1,2,3, and 4:
• Genital and labial herpes.
• Herpetic keratitis.
• Shingles.
• Chicken pox.
• Infectious mononucleosis caused by the Epstein-Barr virus.
• Cytomegalovirus infection.
• Measles of severe course.
• Papillomavirus infection:
• Laryngeal/vocal cord papillomas (fibrotic type).
• Papillomavirus infection of the genitals in men and women.
• Warts.
• Molluscum contagiosum.

Use during pregnancy and lactation

It is not recommended to use the drug during pregnancy and lactation, as the safety of use has not been studied.

Contraindications

• Hypersensitivity to the components of the drug.
• Urolithiasis.
• Arrhythmias.
• Chronic renal failure.
• Children under 3 years of age (body weight up to 15-20 kg).

Side effects

Nervous system disorders:  often – headache, dizziness, fatigue, poor health; infrequently-nervousness, drowsiness, insomnia.

From the gastrointestinal tract:  often-decreased appetite, nausea, vomiting, epigastric pain; infrequently-diarrhea, constipation.

From the side of the hepatobiliary system:  often-increased activity of liver enzymes, alkaline phosphatase.

Skin and subcutaneous fat disorders:  often – itching, rash.

From the side of the kidneys and urinary tract:  infrequently-polyuria.

Allergic reactions:  infrequently – maculopapular rash, urticaria, angioedema.

Musculoskeletal disorders:  often-joint pain, exacerbation of gout.

Other services:  often-an increase in the concentration of blood urea nitrogen.

Interaction

Immunosuppressants may reduce the effectiveness of the drug.

Xanthine oxidase inhibitors and uricosuric agents (including diuretics) may contribute to the risk of increased serum uric acid levels in patients taking Isoprinosinee.

How to take, course of use and dosage

They are taken orally.

Adults: 500 mg to 4 g / day.

Children aged 3-12 years: 50 mg / kg / day.

Both in adults and children, with severe infectious diseases, the dose can be increased individually to 100 mg/kg of body weight/day, divided into 4-6 doses. The maximum daily dose for adults is 3-4 g, for children-50 mg/kg.

The frequency of admission, the course of treatment, and the frequency of repeated courses depend on the indications, the course of the disease, and the treatment regimen.

Overdose

Cases of overdose of Isoprinosinee are not described.

Special instructions

With caution, the drug should be prescribed with xanthine oxidase inhibitors, diuretics, zidovudine, in acute renal failure.

Inosine pranobex, like other antiviral agents, is most effective in acute viral infections if treatment is started at an early stage of the disease (preferably from the first day).

Since inosine is eliminated from the body in the form of uric acid, with prolonged use, it is recommended to periodically monitor the concentration of uric acid in the blood serum and urine. Patients with significantly increased concentrations of uric acid in the body can simultaneously take medications that lower its concentration.

It is necessary to monitor the concentration of uric acid in the blood serum when using inosine pranobex simultaneously with drugs that increase the concentration of uric acid or drugs that violate renal function.

Elderly patients are more likely to have an increase in the concentration of uric acid in the blood serum and urine than in middle-aged patients.

Use with caution in patients with acute hepatic insufficiency, since the drug is metabolized in the liver. In patients with hepatic insufficiency, uric acid levels in the blood serum and urine should be monitored every 2 weeks. Monitoring of the activity of liver enzymes is recommended to be carried out every 4 weeks with long-term courses of treatment with the drug.

Influence on the ability to drive motor vehicles and manage mechanisms

When used in patients engaged in driving vehicles and other potentially dangerous activities, the possibility of dizziness and drowsiness should be taken into account.

Composition

Tablet Form of production

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

5 years

Active ingredient

Inosine Pranobex

Conditions of release from pharmacies

By prescription

Dosage form

Tablets